Furthermore, TKIs are not only used to directly target driver kinases: promising results have also been reported for anti-angiogenic drugs targeting VEGF signaling to prevent tumor vascularization and metastasis [5,107]. The gene discussed is VEGFA; the disease is neoplasm.